Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Phillip Low
Indiana Univ Purdue Univ at Indianapolis, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novosteo, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project, a subcontract from IU to Purdue, entitled “Testing and Targeting of Novel Bone Healing Agents for Improved Fracture Healing” aims to determine whether targeted delivery of novel bone healing agents to the fracture site can improve bone healing outcomes. Prof. Low will collaborate with researchers at IUPUI and IUSM to investigate whether the targeted delivery of thrombopoietin and SRT1720 to the fracture site allows for better healing as compared with non-targeted delivery of the same agents.
Novosteo Inc. is a start-up company based on IP/technologies developed in Prof. Low's laboratories at Purdue and licensed from PRF/OTC. The company aims to reduce the morbidity, mortality and loss of productivity associated with bone fractures by developing drugs that selectively accelerate bone fracture healing by targeting bone anabolic agents to bone fractures and drug limiting accumulation at the fracture site, thereby accelerating and improving the healing process. Prof. Low is an owner and co-founder of the company and continues to pursue and conduct research at Purdue that is, or may become relevant for the business scope and activities of the company.
Therefore, we conclude that the outcome of this research project is, or may become, related to/relevant for the business scope and activities of Novosteo, Inc. Purdue has developed and implemented an FCOI Management Plan for Dr. Low’s activities with the company, please see details below.
Indiana Clinical and Translational Sciences Institute
PROJECT NARRATIVE The Indiana CTSI 3.0 will not only expand translational research across the state, but also address some of the major community health issues faced by Indiana, and the nation. We will find novel approaches to integrating `precision medicine' and `population health', embrace the vision to train a new breed of research workforce skilled in team science and community engagement, and both deepen and expand the integration of research in our health systems. Project Narrative Page 705
Filed on January 14, 2019.
Tell us what you know about Phillip Low's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.